Table 2

Lifetime dose of analgesic use1 and risk of ESRD.

Exposure
 Range grams
 Cases
 Controls
 Adjusted OR2 (95% CI)
All phenacetin-free analgesics
 Low
546
 2030
 1.0 (referent)

Tertile 1,2
 < 217
 213
 1067
 0.75 (0.63–0.90)

Tertile 3
 > = 217
 148
 525
 1.02 (0.81–1.28)
MONOS (single substance)
 Tertile 1,2
 < 185
 185
 975
 0.72 (0.59–0.87)
All monos
 Tertile 3
 > = 185
 129
 479
 0.98 (0.77–1.24)

Other
47
 138
 1.21 (0.84–1.74)
All- no ASA & paracetamol
 Tertile 1,2
 < 65
 62
 322
 0.70 (0.51–0.94)

Tertile 3
 > = 65
 43
 159
 0.90 (0.61–1.31)

Other
256
 1111
 0.87 (0.73–1.03)
COMBIS (combined products)




All combis together
 Tertile 1,2
 < 91
 93
 469
 0.73 (0.56–0.93)

Tertile 3
 > = 91
 75
 235
 1.05 (0.77–1.44)

Other
193
 888
 0.84 (0.69–1.02)
All combis with paracetamol
 Tertile 1,2
 < 83
 87
 401
 0,78 (0.59–1.01)

Tertile 3
 > = 83
 57
 197
 0.95 (0.67–1.35)

Other
217
 994
 0.84 (0.70–1.01)
All combis without paracetamol
 Tertile 1,2
 < 68
 27
 131
 0.75 (0.49–1.16)

Tertile 3
 > = 68
 26
 64
 1.41 (0.85–2.35)

Other
308
 1397
 0.82 (0.69–0.97)
All combis with caffeine
 Tertile 1,2
 < 87
 67
 342
 0.70 (0.52–0.94)

Tertile 3
 > = 87
 55
 169
 1.01 (0.71–1.44)

Other
239
 1081
 0.85 (0.71–1.02)
All combis without caffeine
 Tertile 1,2
 < 57
 44
 237
 0.69 (0.49–0.99)

Tertile 3
 > = 57
 37
 118
 1.15 (0.76–1.73)

Other
280
 1237
 0.84 (0.70–0.99)

1 Lifetime dose of analgesic use: medium = tertile1 and 2; high = tertile 3 vs. referent = no or very low analgesic use (exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) at index date 3 (5 years before first dialysis). The category "other" means: other analgesics than those considered in the specific sub-analysis. The numbers don't add up because participants were classified into the category "other" analgesic, which is not exclusive.

2 Unmatched analysis; adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Adjustment for age group, sex, country, family history chronic renal diseases, exposure with welding/soldering fumes, solvents, and education

van der Woude et al. BMC Nephrology 2007 8:15   doi:10.1186/1471-2369-8-15